Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcohol effects, a new study suggests. Glucagon-like peptide-1 ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Long-acting pharmacotherapies targeting incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

Garrett H. Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.